Auro Labs. (530233)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 185.16% shows strong recent demand traction for a small pharma player.
• Latest quarter is profitable with net profit of ₹1 Cr on sales of ₹9 Cr.
• Profit growth of 100% and a Piotroski F-Score of 6/9 suggest reasonable near-term financial health.
• PEG ratio of 0.58 indicates the stock is not prohibitively expensive if high growth sustains.
• Price has corrected from ₹317 to ₹176.85, reducing some of the speculative froth.

Concerns

• P/E of 82.71 is very high for a company earning only ₹1 Cr quarterly profit.
• ROCE of 0.00% and ROE of 6.82% indicate poor capital efficiency and weak moat.
• Zero dividend yield and promoter holding not disclosed limit investor confidence and transparency.
• Absolute scale is tiny—₹9 Cr quarterly sales—so high growth rates are from a low base and may not be durable.

AI Analysis

This business reminds me to keep my feet on the ground. Auro Labs shows headline growth—sales up 185% and profit up 100%—but I have learned that growth without quality is a dangerous trade. At ₹176.85, I am asked to pay 82.7 times trailing earnings for a company that earns just ₹1 crore a quarter. That is not a margin of safety; it is an act of faith. The book value is ₹69, so price-to-book is 2.56, yet return on equity is only 6.82%. For every hundred rupees of equity, the business generates less than seven rupees—hardly a compounding machine. ROCE at 0.00% is a warning sign; it suggests the capital employed in the business is not earning its keep. There is no dividend, so my only hope is capital appreciation, and after falling from a 52-week high of ₹317 to ₹176, that hope has been wounded. The F-score of 6/9 tells me the balance sheet is not falling apart, but it does not tell me there is a durable moat. The low PEG of 0.58 is comforting only if 100% profit growth continues forever—it will not. In Graham's language, this is closer to speculation than investment. I need stable earnings, margins, and promoters with skin in the game; here promoter holding is not even disclosed. The quarterly numbers are tiny: ₹9 crore sales and ₹1 crore profit. Good for a small pharma story, perhaps, but not enough to justify a ₹110 crore market cap with confidence. I will keep this on my watchlist, not in my portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer